Press Releases SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery. November 6, 2025 SOHM Notes FDA’s Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development. November 4, 2025 New Website Coming Soon September 16, 2023 SOHM, Inc. Expands Its Advisory Board, Appointing Dr. Krishna Bhat, M.D, Ph.D., FACC, as Chief Medical Advisor August 24, 2023 SOHM, Inc. Announce the Appointment of Dr. David Aguilar, Ph.D., as a Chief Operating Officer with the Company with Immediate Effect. August 8, 2023 SOHM Inc. Signs LOI to Acquire Stem Cell Disruptive Technology and Patents August 1, 2023 SOHM Inc. Announces the Closure of Finances-Funding for its Various Projects. July 25, 2023 SOHM Reports on Half-Year Updates and Future Plans for 2023. June 28, 2023 < Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 >
SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery. November 6, 2025
SOHM Notes FDA’s Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development. November 4, 2025
SOHM, Inc. Expands Its Advisory Board, Appointing Dr. Krishna Bhat, M.D, Ph.D., FACC, as Chief Medical Advisor August 24, 2023
SOHM, Inc. Announce the Appointment of Dr. David Aguilar, Ph.D., as a Chief Operating Officer with the Company with Immediate Effect. August 8, 2023
